Response to lenalidomide monotherapy for 102 patients
Response category . | 15 mg twice daily, no. (%) . | 30 mg once daily, no. (%) . | Combined, no. (%) . |
|---|---|---|---|
| Complete remission | 0 (0) | 4 (6) | 4 (4) |
| Partial remission | 5 (14) | 8 (12) | 13 (13) |
| Minor response | 5 (14) | 4 (6) | 9 (9) |
| Stable disease | 14 (40) | 29 (43) | 43 (42) |
| Progression disease | 8 (23) | 12 (18) | 19 (19) |
| Not evaluable/unknown | 3 (9) | 10 (15) | 13 (13) |
| CR + PR | 5 (14) | 12 (18) | 17 (17) |
| CR + PR + MR | 10 (29) | 16 (24) | 26 (25) |
Response category . | 15 mg twice daily, no. (%) . | 30 mg once daily, no. (%) . | Combined, no. (%) . |
|---|---|---|---|
| Complete remission | 0 (0) | 4 (6) | 4 (4) |
| Partial remission | 5 (14) | 8 (12) | 13 (13) |
| Minor response | 5 (14) | 4 (6) | 9 (9) |
| Stable disease | 14 (40) | 29 (43) | 43 (42) |
| Progression disease | 8 (23) | 12 (18) | 19 (19) |
| Not evaluable/unknown | 3 (9) | 10 (15) | 13 (13) |
| CR + PR | 5 (14) | 12 (18) | 17 (17) |
| CR + PR + MR | 10 (29) | 16 (24) | 26 (25) |
The 102 patients included 35 patients on the 15-mg twice-daily and 67 patients on 30-mg once-daily regimen